Trials / Unknown
UnknownNCT04216771
Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients
Randomized Comparison of Consolidation Treatment in Elderly Patients With Acute Myeloid Leukemia: Idarubicin (IDA) Combined With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 320 (estimated)
- Sponsor
- Fujian Medical University · Academic / Other
- Sex
- All
- Age
- 60 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates Idarubicin (IDA) in combination with the intermediate-dose cytarabine, compared with intermediate-dose cytarabine alone, as a consolidation treatment for elderly AML in first remission.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Idarubicin | Idarubicin 10mg/m²/day, D1 (IV) |
| DRUG | ID cytarabine | Cytarabine 1.5g/m² /12h, D1-D3 (IV) |
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2022-05-01
- Completion
- 2024-05-01
- First posted
- 2020-01-03
- Last updated
- 2020-01-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04216771. Inclusion in this directory is not an endorsement.